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Abstract
Background: The PHArmacogenetic study of Statins in the Elderly at risk (PHASE) is a genome wide association
study in the PROspective Study of Pravastatin in the Elderly at risk for vascular disease (PROSPER) that investigates
the genetic variation responsible for the individual variation in drug response to pravastatin. Statins lower LDL-
cholesterol in general by 30%, however not in all subjects. Moreover, clinical response is highly variable and
adverse effects occur in a minority of patients. In this report we first describe the rationale of the PROSPER/PHASE
project and second show that the PROSPER/PHASE study can be used to study pharmacogenetics in the elderly.
Methods: The genome wide association study (GWAS) was conducted using the Illumina 660K-Quad beadchips
following manufacturer’s instructions. After a stringent quality control 557,192 SNPs in 5,244 subjects were available
for analysis. To maximize the availability of genetic data and coverage of the genome, imputation up to 2.5 million
autosomal CEPH HapMap SNPs was performed with MACH imputation software. The GWAS for LDL-cholesterol is
assessed with an additive linear regression model in PROBABEL software, adjusted for age, sex, and country of
origin to account for population stratification.
Results: Forty-two SNPs reached the GWAS significant threshold of p = 5.0e-08 in 5 genomic loci (APOE/APOC1;
LDLR; FADS2/FEN1; HMGCR; PSRC1/CELSR5). The top SNP (rs445925, chromosome 19) with a p-value of p = 2.8e-30
is located within the APOC1 gene and near the APOE gene. The second top SNP (rs6511720, chromosome 19)
with a p-value of p = 5.22e-15 is located within the LDLR gene. All 5 genomic loci were previously associated with
LDL-cholesterol levels, no novel loci were identified. Replication in WOSCOPS and CARE confirmed our results.
Conclusion: With the GWAS in the PROSPER/PHASE study we confirm the previously found genetic associations
with LDL-cholesterol levels. With this proof-of-principle study we show that the PROSPER/PHASE study can be used
to investigate genetic associations in a similar way to population based studies. The next step of the PROSPER/
PHASE study is to identify the genetic variation responsible for the variation in LDL-cholesterol lowering in
response to statin treatment in collaboration with other large trials.
Background
Cardiovascular disease is the leading cause of death in
industrialized countries at old age. Advancing age is one
of the most important risk factors for cardiovascular dis-
ease [1]. With the rising number of elderly people in our
society cardiovascular disease has a major impact on
healthcare [2]. The prevention of cardiovascular disease
is critically dependent on lipid lowering therapy includ-
ing the 3-hydroxymethyl-3-methylglutaryl coenzyme A
(HMG-CoA) reductase inhibitors (statins). Statins are
the most prescribed class of drugs worldwide and ther-
apy is generally associated with a reduction of cardiovas-
cular events by 20-30%. However, clinical response is
highly variable and adverse effects occur in a minority
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of patients [3]. Recent research provides evidence that
genetic variation contributes importantly to this variable
drug response [4].
Pharmacogenomics focuses on unraveling the genetic
determinants of such variable drug responses, both in
intended, beneficial effects and unintended, adverse
effects [5]. Therefore, we here present the PHArmacoge-
netic study of Statin in the Elderly at risk (PHASE) a
genome wide association study (GWAS) in the PRO-
spective Study of Pravastatin in the Elderly at Risk for
vascular disease (PROSPER)[6] investigating the genetic
variation responsible for the individual variation in drug
response funded by the European Union’s Seventh Fra-
mework Programme. To validate the GWAS performed
in the PHASE study, we executed a proof-of-principle
study to investigate the underlying genetic variation in
LDL cholesterol levels.
Recent GWA studies have identified several new loci
that influence circulating levels of blood lipids with
around 95 loci showing statistical associations with circu-
lating total cholesterol levels, HDL cholesterol, LDL cho-
lesterol, and triglycerides [7]. These GWA studies are
executed in population based studies with various age
groups, however the elderly (age > 75 years) are rarely
represented in these studies. With this proof-of-principle
study we provide a testing frame to show that the PROS-
PER/PHASE study has sufficient statistical power to find
genome wide statistical significant associations in quanti-
tative traits such as LDL cholesterol in an elderly popula-
tion. We replicated our findings from the PROSPER/
PHASE study in two independent cohorts to validate that
our results contain no false positive findings.
Methods
Study population
PROSPER was an investigator-driven, prospective multi-
national randomized placebo-controlled trial to assess
whether treatment with pravastatin diminishes the risk
of major vascular events in the elderly [6;8]. Between
December 1997 and May 1999, we screened and
enrolled subjects in Scotland, Ireland, and the Nether-
lands. Men and women aged 70-82 years were recruited
if they had pre-existing vascular disease or were at
increased risk of such disease because of smoking,
hypertension, or diabetes. A total number of 5804 sub-
jects, of whom more than 50% was female, were ran-
domly assigned to pravastatin or placebo. Various
clinical laboratory measurements were carried out like
inflammatory markers (CRP and various cytokines) and
other biochemical substrates (e.g. glucose, leptin) at
baseline and during follow-up. The protocol of the
PROSPER study meets the criteria of the Declaration of
Helsinki and was approved by the Medical Ethics Com-
mittees of each participating institution. Written
informed consent was obtained from all participating
subjects.
LDL cholesterol
Plasma lipids and lipoproteins were measured twice dur-
ing the screening phase, i.e. at the beginning and end of
the single-blind, placebo “run-in” phase according to the
standardized Lipid Research Clinics protocol. Baseline
LDL cholesterol levels were taken as the average of
these 2 determinations prior to randomization to statin
treatment. Total cholesterol (TC), HDL cholesterol, and
triglycerides were assessed after an overnight fast, LDL
cholesterol was calculated by the Friedewald formula, as
previously described [8].
Genotyping
The genotyping was conducted using the Illumina 660-
Quad beadchips following manufacturer’s instructions.
These beadchips contain 657,366 single nucleotide poly-
morphism (SNP) and copy number variants (CNV)
probes. After genotyping, samples and genetic markers
were subjected to a stringent quality control protocol.
From the 5763 samples with DNA available that under-
went genotyping, 519 samples (9%) were excluded dur-
ing the quality control (Figure 1). Excluded were 18
duplicated samples, 219 samples with a call rate <
97.5%, 11 samples with an excess for heterozygosity, 40
samples of non-caucasian origin, 170 samples with
familiar relationships (IBD > 0.35), and 61 samples with
a gender mismatch. From the 657,366 probes on the
beadchips, 95,876 probes were filtered based on CNV
intensity. Moreover, 4,298 SNPs were excluded with a
call rate < 95%, leaving us with 557,192 SNPs for analy-
sis. To maximize the availability of genetic data and cov-
erage of the genome, imputation up to 2.5 million
autosomal CEPH HapMap SNPs was performed with
MACH imputation software based on the Hapmap built
II release 23. To assess accuracy of the imputed geno-
types, we compared the imputation output with SNPs
that had been previously genotyped on other platforms.
Statistical Analysis
Genome wide association analysis was performed with
PROBABEL software specialized in genetic association
analysis with imputed data taking the probability of the
genotype into account (http://www.genabel.org/). With
analyzing imputed genotypes, the observed allele count
is replaced by the imputation’s estimated dosage. For
the continuous trait, baseline LDL cholesterol levels, an
additive linear regression model was used to assess esti-
mates and standard errors. The model was adjusted for
sex and age, and country to correct for the within-study
population structure. Standard errors for the regression
estimates were calculated with model-robust methods.
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The analysis of 2.5 million SNPs at once poses a multi-
ple testing problem. After the use of a Bonferroni cor-
rection, the threshold for genome wide significant
results was set at 5.0e-08.
Replication
Associations with a genome-wide significant p-value of
5.0e-08 were replicated in two independent cohorts, the
West of Scotland Coronary Prevention Study
Samples 
5,763
18 duplicated 
samples excluded
219 samples 
excluded with call 
rate <97.5%
11 samples 
excluded with 
excess of 
heterozygostiy
40 samples 
excluded of non-
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170 samples 
excluded with 
familiar 
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61 samples 
excluded with 
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Final 5244 
samples
SNPs
657,366
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for analysis
Figure 1 Flow chart of the Quality Control of the PROSPER/PHASE study.
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(WOSCOPS)[9] and the Cholesterol and Recurrent
Events (CARE) trial [10]. The WOSCOPS study was a
double blind randomized placebo-controlled clinical trial
in which 6595 men (age range 45-64 years)with
hypercholesterolemia and no history of myocardial
infarction were treated with 40 mg pravastatin (N =
3302) or placebo (N = 3293). GWAS data and baseline
LDL cholesterol levels were available for 431 subjects.
The CARE study was a double blind randomized pla-
cebo-controlled clinical trial in which 4159 patients (age
range 21-75 years) were treated with 40 mg pravastatin
(N = 2081) or placebo (N = 2078). GWAS data and
baseline LDL cholesterol levels were available for 751
subjects. The significance level for the replication SNPs
was set at p-value < 0.05.
Results
Table 1 shows the baseline characteristics of the subjects
participating in the PROSPER and the PROSPER/
PHASE study. This table shows that the genotyped sub-
jects in the PROSPER/PHASE study are representative
of the total study population of the PROSPER study,
since no major discrepancies exist between the two
study sets. The mean age of all subjects at study entry
was 75.3 years and about 50% of the participants were
female.
In Figure 2 the QQ-plot of the genome-wide associa-
tion study with baseline LDL levels within the PROS-
PER/PHASE study is shown. In this plot it is shown that
no genomic inflation has occurred in this analyses
Table 1 Baseline characteristics of the PROSPER/PHASE study
PROSPER study (n = 5804) PROSPER/PHASE study (n = 5244)
Continuous variables (mean, SD)
Age (years) 75.3 (3.3) 75.3 (3.4)
Education (years) 15.1 (2.0) 15.1 (2.0)
Systolic blood pressure (mmHg) 154.7 (21.8) 154.6 (21.9)
Diastolic blood pressure (mmHg) 83.8 (11.5) 83.7 (11.4)
Height (cm) 165.2 (9.4) 165.2 (9.4)
Weight (kg) 73.4 (13.4) 73.3 (13.4)
Body mass index (kg/m2) 26.8 (4.2) 26.8 (4.2)
Total cholesterol (mmol/L) 5.7 (0.9) 5.7 (0.9)
LDL cholesterol (mmol/L) 3.8 (0.8) 3.8 (0.8)
HDL cholesterol (mmol/L) 1.3 (0.3) 1.3 (0.4)
Triglycerides (mmol/L) 1.5 (0.7) 1.5 (0.7)
Categorical variables (n, %)
Males 2804 (48.3) 2524 (48.1)
Current smoker 1558 (26.8) 1392 (26.5)
History of diabetes 623 (10.7) 544 (10.4)
History of hypertension 3592 (61.9) 3257 (62.1)
History of angina 1559 (26.9) 1424 (27.2)
History of claudication 390 (6.7) 354 (6.8)
History of myocardial infarction 776 (13.4) 708 (13.5)
History of stroke or TIA 649 (11.2) 586 (11.2)
History of vascular disease* 2565 (44.2) 2336 (44.5)
*Any of stable angina, intermittent claudication, stroke, transient ischemic attack, myocardial infarction, peripheral artery disease surgery, or amputation for
vascular disease more than 6 months before study entry.
Lambda = 1.077
Figure 2 QQ-plot for the GWAS on baseline LDL cholesterol in
the PROSPER/PHASE study.
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(lambda = 1.077) and that population stratification is
sufficiently controlled for. In Figure 3 the results of the
genome-wide association study with baseline LDL cho-
lesterol levels within the PROSPER/PHASE study are
depicted in a Manhattan plot. Forty-two SNPs in five
genomic loci, APOE/APOC1, LDLR, FADS2/FEN1,
HMGCR, and PSRC1/CELSR5, reached the genome-
wide significant p-value of 5.0e-08. In table 2 a summary
of the five genomic loci and their corresponding SNPs is
given. The top SNP (rs445925, Chr. 19) with a p-value
of p = 2.8e-30 is located within the APOC1 gene and
near the APOE gene. Sixteen other SNPs in the same
genomic region were also found to be associated with
LDL cholesterol levels. The second top SNP (rs6511720,
Chr. 19) with a p-value of p = 5.22e-15 is located within
the LDLR gene. The three other genomic regions
included the HMGCR (Chr.5), FADS2/FEN1 (Chr. 11),
PSRC1/CELSR5 (Chr. 1) genes. All 5 genomic loci were
previously found in association with LDL cholesterol
levels and no novel loci were identified.
We replicated the positive associations with genome-
wide significant p-values in two independent cohorts,
the WOSCOPS study and the CARE trial (table 3). Of
our five genomic loci that were significantly associated
with baseline LDL cholesterol levels we selected the top
SNP for replication in both replication cohorts. If the
SNP was not genotyped in their GWAS analysis, we
chose a proxy in high linkage disequilibrium (r2 > 0.5%)
for that SNP. These SNPs were associated with baseline
LDL levels before randomisation to statin treatment in
both studies. Three out of the five loci (APOE/APOC1;
HMGCR; PSRC1/CELSR5) replicated in one or two
replication cohorts (p < 0.05). The two other loci (LDLR
and FADS2/FEN1) showed similar trends as shown in
the discovery cohort, although they did not reach statis-
tical significance (table 3).
Discussion
With this first proof-of principle study we show that the
PROSPER/PHASE GWAS can confirm previously found
genetic associations with LDL-cholesterol levels. This
proof-of-principle study indicates that the PROSPER/
PHASE study is likely to be capable of detecting geno-
mic regions responsible for the variation in various
other quantitative traits. With almost 6000 samples in
the PROSPER/PHASE study and access to various repli-
cation studies, the PROSPER/PHASE study can provide
a good testing frame to identify the genetic variation
responsible for the variation in LDL-cholesterol lowering
in response to statin treatment.
The main locus responsible for the person-to-person
variation in LDL-cholesterol levels is the chromosome
19 locus, which contains the APOE, APOC1, and LDLR
genes. Other important loci included the HMGCR locus
on chromosome 5, FADS2/FEN1 locus on chromosome
11, and the PSRC1/CELSR5 locus on chromosome 1.
The five genomic loci that were associated with varia-
tion in LDL-cholesterol levels in the PHASE GWAS
study were all genomic regions that were previously
APOE/APOC1
LDLR
FADS2/FEN1HMGCRPSRC1/CELSR5
Figure 3 Manhattan plot for the GWAS on baseline LDL
cholesterol in the PROSPER/PHASE study.
Table 2 Genomic loci with a genome wide significant p-value < = 5
Chr. Gene Number of SNPs TopSNP Variant MAF Beta SE p-value Ref*
19 APOE
APOC1
17 rs445925 G > A 0.11 -0.33 0.03 2.8e-30 (7;11-14;18;19)]
19 LDLR 5 rs6511720 G > T 0.13 -0.19 0.02 5.2e-15 (7;11;13;14;19)]
5 HMGCR 5 rs258494 G > C 0.38 0.10 0.02 1.3e-09 (7;11;13;14;19)]
11 FADS2
FEN1
14 rs174541 C > T 0.38 -0.10 0.02 1.1e-08 (7;11;13;19)]
1 PSRC1
CELSR5
1 rs602633 G > T 0.23 -0.11 0.02 5.0e-08 (7;11-14;16-19)]
Abbreviations: SNP, Single Nucleotide Polymorphism; Chr, Chromosome; MAF, minor allele frequency; SE, standard error. * A list of references in which the same
loci were found.
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reported with LDL cholesterol variation [7;11-19]. Three
out of the five loci were replicated in the WOSCOPS
study and the CARE trial. The LDLR and FADS2/FEN1
loci were not replicated, however these loci were repeat-
edly found to be associated with LDL cholesterol levels
in various other studies with large number of partici-
pants [7;11-14;16;19]. Moreover, both the WOSCOPS
and CARE studies had genotype data available in a
small number of subjects. Therefore, the lack of replica-
tion of these loci in WOSCOPS and CARE was most
likely due to lack of statistical power. Finally, since we
used in the replication studies a proxy SNP for some of
the topSNPs, this may have diluted the effect.
Conclusions
With this proof-of-principle study we show that the
PROSPER/PHASE study can be used to investigate
genetic associations in a similar way to population based
studies. Moreover, we can also assume from these
results that the PROSPER/PHASE study is likely to have
sufficient power to detect genome-wide significant hits
with large effects for other quantitative traits. The next
step of the PROSPER/PHASE study is to identify the
genetic variation responsible for the variation in LDL-
cholesterol lowering in response to statin treatment.
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